News

Complete Response Letter for Ryanodex to treat exertional heat stroke.- Eagle Pharma

Read time: 1 mins

Published:17th Aug 2020

Eagle Pharma has received a further Complete Response Letter for its New Drug Application (“NDA”) for Ryanodex for the treatment of exertional heat stroke (“EHS”). Eagle has decided that it will no longer pursue this indication.

Condition: Exertional Heat Stroke

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Phase III BE HEARD I and II studies of Bimzelx meet primary endpoint in Hidradenitis Suppurativa.- UCB

UCB announced positive top-line results from two Phase III studies, BE HEARD I and BE HEARD II, evaluating the efficacy and safety of Bimzelx (bimekizumab) in adults with moderate to severe hidradenitis suppurativa.

1 mins

Drug news

Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials.- Novartis

Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile.

1 min

Drug news

Initiation of pivotal phase III clinical Trial of LBS 008 in Stargardt disease in the U.S.

Belite Bio, Inc, a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, announced that it has commenced enrollment for the Phase III clinical trial of LBS 008 in patients with Stargardt Disease (STGD1), a progressively blinding disease with no approved treatment

1 min

See all news